Top of this page
Skip navigation, go straight to the content
Company
- A global biopharma focused on severe diseases in two therapeutic areas: central nervous system and immunology
- Global revenue of € 3.1 billion in 2009
- Operations in over 40 countries, supported by approximately
9 000 people - Established in 1928, successful transformation from a hybrid specialty chemical company into a next generation biopharma leader
- Listed on the Euronext Brussels Stock Exchange
- Headquartered in Brussels, Belgium.
